Literature DB >> 21796115

Cancer pharmacogenomics.

S W Paugh1, G Stocco, J R McCorkle, B Diouf, K R Crews, W E Evans.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21796115      PMCID： PMC3646359          DOI： 10.1038/clpt.2011.126

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  42 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 3.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 4.  Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.

Authors:  Gabriele Stocco; Kristine R Crews; William E Evans
Journal:  Expert Opin Drug Saf       Date:  2010-01       Impact factor: 4.250

5.  Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.

Authors:  T E Mürdter; W Schroth; L Bacchus-Gerybadze; S Winter; G Heinkele; W Simon; P A Fasching; T Fehm; M Eichelbaum; M Schwab; H Brauch
Journal:  Clin Pharmacol Ther       Date:  2011-03-30       Impact factor: 6.875

6.  Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.

Authors:  Jun J Yang; Cheng Cheng; Meenakshi Devidas; Xueyuan Cao; Yiping Fan; Dario Campana; Wenjian Yang; Geoff Neale; Nancy J Cox; Paul Scheet; Michael J Borowitz; Naomi J Winick; Paul L Martin; Cheryl L Willman; W Paul Bowman; Bruce M Camitta; Andrew Carroll; Gregory H Reaman; William L Carroll; Mignon Loh; Stephen P Hunger; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Nat Genet       Date:  2011-02-06       Impact factor: 38.330

7.  Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Authors:  L Madlensky; L Natarajan; S Tchu; M Pu; J Mortimer; S W Flatt; D M Nikoloff; G Hillman; M R Fontecha; H J Lawrence; B A Parker; A H B Wu; J P Pierce
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

8.  Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.

Authors:  In Hae Park; Jungsil Ro; Sohee Park; Hyeong-Seok Lim; Keun Seok Lee; Han Sung Kang; So-Youn Jung; Seeyeon Lee
Journal:  Breast Cancer Res Treat       Date:  2011-03-25       Impact factor: 4.872

9.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Authors:  Lisa R Treviño; Noriko Shimasaki; Wenjian Yang; John C Panetta; Cheng Cheng; Deqing Pei; Diana Chan; Alex Sparreboom; Kathleen M Giacomini; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

10.  Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.

Authors:  Barthelemy Diouf; Qing Cheng; Natalia F Krynetskaia; Wenjian Yang; Meyling Cheok; Deqing Pei; Yiping Fan; Cheng Cheng; Evgeny Y Krynetskiy; Hui Geng; Siying Chen; William E Thierfelder; Charles G Mullighan; James R Downing; Peggy Hsieh; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440
View more
  14 in total

Review 1.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 2.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 3.  Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Authors:  Daniel Crona; Federico Innocenti
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 4.  Pharmacogenomics in early-phase clinical development.

Authors:  Tal Burt; Savita Dhillon
Journal:  Pharmacogenomics       Date:  2013-07       Impact factor: 2.533

Review 5.  Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation.

Authors:  Yun R Li; John E Levine; Hakon Hakonarson; Brendan J Keating
Journal:  Eur J Hum Genet       Date:  2013-11-20       Impact factor: 4.246

6.  Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

Authors:  Lynn G Dressler; Allison M Deal; Kouros Owzar; Dorothy Watson; Katherine Donahue; Paula N Friedman; Mark J Ratain; Howard L McLeod
Journal:  J Natl Cancer Inst       Date:  2015-07-09       Impact factor: 13.506

7.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

8.  PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.

Authors:  Gabriele Stocco; Wenjian Yang; Kristine R Crews; William E Thierfelder; Giuliana Decorti; Margherita Londero; Raffaella Franca; Marco Rabusin; Maria Grazia Valsecchi; Deqing Pei; Cheng Cheng; Steven W Paugh; Laura B Ramsey; Barthelemy Diouf; Joseph Robert McCorkle; Terreia S Jones; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Hum Mol Genet       Date:  2012-07-30       Impact factor: 6.150

9.  Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.

Authors:  Deolinda Pereira; Joana Assis; Mónica Gomes; Augusto Nogueira; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2016-01-23       Impact factor: 2.953

Review 10.  Cancer pharmacogenomics: strategies and challenges.

Authors:  Heather E Wheeler; Michael L Maitland; M Eileen Dolan; Nancy J Cox; Mark J Ratain
Journal:  Nat Rev Genet       Date:  2012-11-27       Impact factor: 53.242
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.